Key elements of bioanalytical method validation for macromolecules

• DOI: 10.1208/aapsj0902017
• Publication Date: 2007-07-05T19:10:02Z
• Authors: Marian Kelley; Binodh DeSilva
• Keywords: Immunoassay; Macromolecular Substances; Antibodies, Monoclonal; Reproducibility of Results; Reference Standards; Ligands; Sensitivity and Specificity; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Pharmaceutical Preparations; Indicators and Reagents

The Third American Association of Pharmaceutical Scientists/US Food and Drug Administration (FDA) Bioanalytical Workshop, which was held May 1 and 2, 2006, in Arlington, VA, addressed bioanalytical assays that are being used for the quantification of therapeutic candidates in support of pharmacokinetic evaluations. One of the main goals of this workshop was to discuss best practices used in bioanalysis regardless of the size of the therapeutic candidates. Since the last bioanalytical workshop, technological advancements in the field and in the statistical understanding of the validation issues have generated a variety of interpretations to clarify and understand the practicality of using the current FDA guidance for assaying macromolecular therapeutics. This article addresses some of the key elements that are essential to the validation of macromolecular therapeutics using ligand binding assays. Because of the nature of ligand binding assays, attempts have been made within the scientific community to use statistical approaches to interpret the acceptance criteria that are aligned with the prestudy validation and in-study validation (sample analysis) processes. We discuss, among other topics, using the total error criterion or confidence interval approaches for acceptance of assays and using anchor calibrators to fit the nonlinear regression models.